A Glimpse Into the Future of Myeloma Patient Management

Overview

Provider Statement

Jointly provided by

Activity Description

In the last 18 years, oncology clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. In this time, 16 new drugs have been approved by the US Food and Drug Administration (FDA) for use in MM—including 10 in the last 6 years alone. The rapidity with which clinical data relating to MM therapy (including for smoldering multiple myeloma) continues to evolve and emerge all but ensures that the MM treatment paradigm will continue to change significantly in the future.

Developed to help hematologist-oncologists prepare for advancements in MM patient management protocols, this activity features presentations on current and evolving MM patient care practices and discussions of how they are likely to evolve over the next 3 to 5 years.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with MM.

Learning Objectives

Upon completion of this activity, participants should be better able to (1) interpret the cytogenetic, molecular, and other standard staging tests used to define risk and prognosis for patients with myeloma precursor conditions and MM; (2) distinguish between the indicated uses and mechanisms of action of current and emerging treatment regimens; (3) evaluate emerging data regarding the approach to MRD testing; (4) develop individualized management plans for MM patients based on risk and cytogenetic and genomic data

Medium

Online activity

Faculty

Hearn Jay Cho, MD, PhD—Program Co-Chair
Chief Medical Officer
Multiple Myeloma Research Foundation
Norwalk, Connecticut
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Keith Stewart, MBChB—Program Co-Chair
Vice President, Cancer, University Health Network
Medical Director, Princess Margaret Cancer Centre
Regional Vice President, Toronto Central South, Ontario Health
Richard H. Clark Chair in Cancer Medicine
Toronto, Ontario, Canada

Amrita Y. Krishnan, MD
Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor, Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Medical Center
Duarte, California

Elisabet E. Manasanch, MD
Associate Professor
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
University of California San Francisco
San Francisco, California

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Penn State College of Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees to participate in the activity. During the period of January 24, 2022 through January 24, 2023, participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the posttest (achieving a passing grade of 70% or greater) and program evaluation. Certificates can be printed immediately.

Disclosures

In accordance with the ACCME Standards for Integrity and Independence, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are discussed in the CME activity content over which the individual has control.

All of the relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:

Hearn J. Cho, MD, PhD, has disclosed the following relevant financial relationships:
Research grant: Bristol Myers Squibb/Celgene, Takeda

Paul G. Richardson, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: AstraZeneca, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, Takeda
Research Grant: Bristol Myers Squibb/Celgene, Karyopharm, Oncopeptides, Takeda

A. Keith Stewart, MBChB, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, GlaxoSmithKline, Janssen, Oncopeptides

Amrita Y. Krishnan, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol Myers Squibb, GlaxoSmithKline, Janssen
Research Grant: Janssen
Scientific Advisory Board: Sutro BioPharma
Speakers Bureau: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Takeda
Stock Ownership: Bristol Myers Squibb

Elisabet E. Manasanch, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Adaptive Biotechnologies, Celgene, GlaxoSmithKline, Janssen, Sanofi, Secura Bio, Takeda
Research Grant: JW Pharma, Merck, Novartis, Quest Diagnostics, Sanofi

Nina Shah, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, Sanofi
Research Grant: Bluebird Bio, Celgene/Bristol Myers Squibb, Janssen, Nektar, Poseida, Sutro Biopharma, Teneobio

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation 
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RedMedEd
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, AbbVie, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, CURE, or Targeted Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, AbbVie, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, CURE, and Targeted Oncology do not recommend the use of any agent outside the labeled indications.

Privacy

This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by Penn State College of Medicine. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine or RedMedEd. For more information, contact Penn State College of Medicine at ContinuingEd@hmc.psu.edu and reference activity code G6759-22-T or RedMedEd at education@redmeded.com.

The Wyanoke Group Privacy Policy

CME Questions

For questions regarding CME credit, please contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6759-22-T.

For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or education@redmeded.com.

Hardware/Software Requirements

A computer, Apple iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android devices (OS 11 or higher) with an Internet connection using one of these browsers: Chrome, Firefox, Safari, Microsoft Edge

Copyright Statement

© 2022. This CME-certified program is held as copyrighted by Penn State College of Medicine, MMRF, and RedMedEd. Through this notice, Penn State College of Medicine, MMRF, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.